Autoimmune biotech Landos Biopharma files for a $100 million IPO

Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. The company leverages its proprietary AI-based precision medicine LANCE platform to id


Total Pageviews


PyndanEX - Allocated Industries

Endeavor To Where It Matters! | Economic Calendar by TradingView

ΛPP.IPΛI 🏄 Powered by Surfing Waves!